• Explore /
  • Poster
  • / Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009).

Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009).

Abstract Poster

Authors

Suresh Ramalingam

Suresh S. Ramalingam

The Winship Cancer Institute of Emory University, Atlanta, GA

Suresh S. Ramalingam , Pasi A. Janne , Tony Mok , Kenneth O'Byrne , Michael J. Boyer , Hui Zhang , Jane Q. Liang , Jim P. Doherty , Ian Taylor , Cecile A. Mather , Joseph P. O'Connell , Luis Paz-Ares

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Lung Cancer - Non-small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01360554

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 8018)

DOI

10.1200/jco.2014.32.15_suppl.8018

Abstract #

8018

Poster Bd #

32

Abstract Disclosures

Similar Posters

First Author: Michael J. Boyer

First Author: Osvaldo Rudy Aren

First Author: A. Sandler

First Author: Sung Yong Oh